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Background. There are relatively few studies published examining the sensitivity and speciﬁcity of potassium hydroxide (KOH)
smear and fungal culture examination of tinea pedis. Objective. To evaluate the sensitivity and speciﬁcity of KOH smear and
fungal culture for diagnosing tinea pedis. Methods. A pooled analysis of data from ﬁve similarly conducted bioequivalence trials
for antifungal drugs was performed. Data from 460 patients enrolled in the vehicle arms of these studies with clinical diagnosis
of tinea pedis supported by positive fungal culture were analyzed 6 weeks after initiation of the study to determine the sensitivity
and speciﬁcity of KOH smear and fungal culture. Results. Using clinical assessment as the gold standard, the sensitivities for KOH
smear and culture were 73.3% (95% CI: 66.3 to 79.5%) and 41.7% (34.6 to 49.1%), respectively. The respective speciﬁcities for
culture and KOH smear were 77.7% (72.2 to 82.5%) and 42.5% (36.6 to 48.6%). Conclusion. KOH smear and fungal culture are
complementary diagnostic tests for tinea pedis, with the former being the more sensitive test of the two, and the latter being more
speciﬁc.
1.Introduction
Tinea pedis is a dermatophyte infection of the plantar feet
or toe web spaces most commonly caused by Trichophyton
rubrum, Trichophyton mentagrophytes, and Epidermophyton
ﬂoccosum [1]. It is believed that up to 70% of the world’s
population will be aﬀected by tinea pedis at some point in
their lives [2].
Although often easily diagnosed by clinical examination,
conﬁrmationoftineapedisinfectionbydiagnostictestshelps
in diﬀerentiating the disease from other skin conditions that
produce a similar clinical picture [3]. Two commonly used
laboratorymethodsforthediagnosisoftineapedisarefungal
cultureandpotassiumhydroxide(KOH)examinationofskin
scrapings for fungal elements. While we often rely on KOH
smear and/or culture in the diagnosis of tinea pedis, the
sensitivity and speciﬁcity of these procedures have only been
reported in a limited number of studies. In 1993, Miller and
Hodgson reported a sensitivity of 77% of KOH examination
using culture as a gold standard (i.e., of 139 positive cultures,
107 were positive by KOH examination). Interestingly, of
194 culture-negative specimens, 74 were positive by KOH
examination, yielding a speciﬁcity of 62% [4]. Of these, one
must assume that some of these positive KOH examinations
were true positives in spite of negative culture. That is, the
discordance between fungal culture and KOH examination
results is too great. Therefore, one must question the validity
of using culture as a gold standard.
In one recent study of 2,427 patients, the sensitivity
and speciﬁcity of KOH examination of tinea pedis were
found to be 95.7% and 69.6%, respectively, relative to a
culture gold standard [5]. Interestingly, the study found
that the percentage of patients presenting with a clinical
diagnosis of tinea pedis that had skin cultures positive for2 Dermatology Research and Practice
fungus were only 36.6%, raising a question as to whether
culture is the optimal gold standard by which to evaluate
diagnostic tests for tinea pedis. At least one other study
showed similar incongruence between the clinical diagnosis
of tinea pedis and fungal culture, with less than a third of
patients presenting with a clinical diagnosis of the disease
having positive cultures [3]. Examples of how culture may
miss a diagnosis of tinea pedis include sampling error
from the aﬀected foot, using defective culture medium, and
mishandling of the culture medium.
Establishing a gold standard for a test is sometimes
straightforward but sometimes diﬃcult, as is the case for
tineapedis.Forlungcancer,forexample,onemightcompare
chest X-ray relative to a gold standard of tissue histology.
Here, there is little question that tissue histology nearly
uniformly makes or breaks the diagnosis whereas chest X-
ray may leave you guessing. And, indeed, one naturally
assigns speciﬁcity and sensitivity to the test relative to a gold
standard, which axiomatically must have essentially 100%
sensitivity and 100% speciﬁcity. With fungal culture, one
does not always culture out positive organisms in the face
of a true infection, as deﬁned by one possible gold standard
of positive KOH smear and clinical evidence of infection.
Indeed, a second sampling at the same or later date may
reveal a positive culture even though the initial sample gave a
negativeresult.Whilesomemaywishtodeﬁnefungalculture
as the axiomatic gold standard for KOH exam (because you
can see and speciate the exact organism), it is not the same
caliber of gold standard as, say, tumor histology might be for
a chest X-ray in lung cancer.
The dilemma of a lack of gold standard for tinea pedis
diagnosis thus poses a problem. In the clinic, we accept
positivity of culture or KOH smear as indicative of infection
because, even in the event of a false positive, harm from
topical treatment is nil. Negative tests may not deter therapy
on the basis of clinical suspicion since the tests are imperfect,
and again, risks of topical therapy are nil. If the disease did
not improve after a 1-week trial of topical antifungals, other
diagnoses, such as plantar psoriasis, might be entertained
and treated with, say, a topical steroid. What is occurring
is that treatment is being chosen on the basis of a positive
clinical diagnosis, albeit that culture and KOH smears
may be supportive of that decision when positive. That is,
clinical diagnosis—albeit imperfect and subjective—is the
gold standard in practice.
For clinical trials, such as those used to prove eﬃcacy at
the U.S. Food and Drug Administration (FDA), the choice
of gold standard by which to deﬁne infection would ideally
be perfect and objective—a luxury we do not have with one
metric at one point in time. In this case, the concern is not in
one test predicting a true outcome but rather in the outcome
itself. Therefore, for FDA studies, one deﬁnes positive as a
triple positive (clinical, KOH, and culture) and negative as a
t r i p l en e g a t i v e[ 6].
In this pooled analysis of data from ﬁve similarly
conducted bioequivalence trials for antifungal drugs, we seek
to establish the sensitivity and speciﬁcity of KOH and culture
in the diagnosis of tinea pedis, using clinical assessment as
the gold standard.
2. Methods
2.1. Study Population and Endpoints. The 484 patients in
thispooledanalysiswereparticipants,randomizedtovehicle,
in ﬁve previous 3-way, randomized, parallel group, double-
blind,vehicle-controlledclinicalbioequivalencetrialsinvolv-
ing the use of test and reference antifungal agents against
tinea pedis infection. Institutional review board approval
was obtained for each of the ﬁve studies. The earliest
study (STUDY #1), Nizoral (ketoconazole) cream 2% versus
ketoconazole cream2%, wasconductedin 2001 and involved
292 patients (192 active and 100 vehicle). The second
study (STUDY #2), Spectazole (econazole nitrate) cream
1% versus econazole nitrate cream 1%, was conducted in
early 2002 and involved 252 patients (165 active and 87
vehicle). The third study (STUDY #3), Lotrisone (clotrima-
zole 1%/betamethasone dipropionate 0.05%) lotion versus
clotrimazole 1%/betamethasone dipropionate 0.05% lotion,
was conducted in late 2002 and involved 399 patients (312
activeand87vehicle).Thefourthstudy(STUDY#4),Loprox
(ciclopirox olamine) cream 0.77% versus ciclopirox olamine
cream 0.77%, was conducted in early 2003 and involved
462 patients (373 active and 89 vehicle). The latest study
(STUDY#5),Loprox(ciclopiroxolamine)topicalsuspension
0.77% versus ciclopirox olamine topical suspension 0.77%,
was conducted in late 2003 and involved 603 patients (482
active and 121 vehicle). All of the studies selected for this
pooled analysis were similar in terms of study design, patient
characteristics,inclusionandexclusioncriteria,diseaseentity
investigated, treatment regimens, and outcome variables
measured.
All participants in these studies were either healthy males
or nonpregnant, nonnursing females, aged 18 and over.
At study onset, the participants were diagnosed clinically
by one of the authors (HY) with tinea pedis, deﬁned by
an erythema score of at least 1/3, a pruritus score of
at least 1/3, a scaling score of at least 2/3, and a total
score of at least 4/18. The participants also had a positive
KOH smear and had a positive culture for Trichophyton
rubrum, Trichophyton mentagrophytes,o rEpidermophyton
ﬂoccosum prior to randomization. There were 1,524 patients
randomized to receive the active treatments and 484 to
receive the vehicles.
The subpopulations of interest in this pooled analysis
were patients randomized to the vehicle arms in the above-
mentioned therapeutic equivalence trials. Fungal culture
(positive/negative), KOH smear (positive/negative), and
clinical eﬃcacy (presence/absence of disease) assessments
were made 4 and 6 weeks after initiation of a 4-week
treatmentregimen.Clinicalassessmentwasmadeforatarget
area of one foot using each of six clinical parameters—
erythema, scaling, ﬁssuring, bulla formation, itching, and
burning—evaluated on a 0–3 scale, where 0 = none, 1 =
mild, 2 = moderate, and 3 = severe. Clinical cure was
achieved if severity scores for each of the six parameters were
0 or 1 with a combined score of 2 or less. That said, for
the purposes of this manuscript, it is not cure per se that
is of interest, but rather, clinical assessment (regardless of
outcome) as it compares to KOH and culture outcomes.Dermatology Research and Practice 3
The vehicle arms of the studies, rather than both vehicle
andactivearms,werechosensimplytoenrichtheproportion
of positive KOH or culture readings at the end of the study;
however, on theoretical grounds, we could have used all
patients. The vehicles were not identical between studies,
but they need not be. The current analysis is concerned
only with the correlation of KOH or culture to a separate,
gold standard assessment, regardless of what cream was used
in the area being evaluated. Sensitivity and speciﬁcity are
inherent properties of a test. It does not matter how the
disease cleared (i.e., what creams, if any, were used) but
rather, how well the test (KOH or culture) reﬂects the actual
condition (the gold standard). Also, the assessment is of a
speciﬁc area of the foot from which material for KOH and
culturewastaken.Clinicalassessmentoftheareainquestion,
rather than of the whole foot, is of interest because we are
examining KOH and culture of material taken from that
speciﬁc area.
The requirement of culture, KOH, and clinically posi-
tive patients at baseline was also theoretically extraneous;
however, it served to decrease the number of clinical false
positives due to nondermatophyte conditions. In reality,
sensitivity and speciﬁcity, and the derivative values of PPV
and NPV, are calculated from an assessment at one point
in time. At that time, true positives and true negatives are
deﬁned by the choice of gold standard, in this case clinical
assessment. In this vein, we arbitrarily chose six weeks as the
time point to compare all the studies. In theory, we could
have used the four-week data alone or combined the four-
and six-week data. It was felt that the pooled six-week data
provided a suﬃcient sample size to draw conclusions, which
a r ea tb e s tar a n g eo fv a l u e sa n y w a y .
Finally, we opted not to analyze the combination of
KOH smear and culture relative to clinical assessment.
The permutations of double positives, double negatives, or
discordantpairsofKOHsmearandculturerelativetoclinical
assessment are many. The deﬁnition of a “positive test” is
debatable—that is, are only double positives counted or are
discordant pairs (that by deﬁnition contain one positive)
counted? The deﬁnition aﬀects the outcome of sensitivity
and speciﬁcity. There would be too many tables to satisfy
all readers’ curiosities. The purpose of this manuscript
w a st oe v a l u a t ee i t h e rK O Hs m e a ro rc u l t u r er e l a t i v et oa
gold standard. For the purposes of rigorous FDA studies,
positive disease is deﬁned as a positive KOH smear and
culture and clinical assessment; negative disease is deﬁned
as a negative KOH smear and negative culture and negative
clinical assessment.
2.2. KOH Smear and Culture Assay. After cleaning with
isopropanol wipes, scrapings were taken with a sterile 15-
blade from areas of the foot with the most clinically apparent
disease. These areas were typically interdigital and scaling.
H a rv e s t e ds c a l ew a ss m e a r e do n t oas l i d e ,a n dad r o po fK O H
10% solution was then added, followed by coverslip and
gentle heating with the ﬂame from a match. Under 40x, the
specimen was observed for hyphae, arthroconidia, and yeasts
within 3 hours of preparation. Sabouraud dextrose agar,
Littman-Oxgall agar, and Mycosel were inoculated via sterile
Table 1: Age in years by study.
Study N Mean Standard Minimum Maximum
Deviation
STUDY #1 100 37.1 12.2 18 70
STUDY #2 87 38.6 14.0 19 83
STUDY #3 87 39.0 12.8 19 71
STUDY #4 89 39.5 13.4 18 81
STUDY #5 121 39.2 13.1 18 76
Overall 484 38.6 13.1 18 83
Table 2: Race distribution by study.
Study Caucasian African Hispanic Other
N % N % N % N %
STUDY #1 61 61.0 14 14.0 24 24.0 1 1.0
STUDY #2 73 83.9 6 6.9 7 8.1 1 1.2
STUDY #3 52 59.8 13 14.9 19 21.8 3 3.5
STUDY #4 58 65.2 10 11.2 19 21.4 2 2.3
STUDY #5 87 71.9 6 5.0 27 22.3 1 0.9
Overall 331 68.4 49 10.1 96 19.8 8 1.7
Table 3: Sex distribution by study.
Study Male Female
N % N %
STUDY #1 69 69.0 31 31.0
STUDY #2 67 77.0 20 23.0
STUDY #3 70 80.5 17 19.5
STUDY #4 70 78.7 19 21.4
STUDY #5 92 76.0 29 24.0
Overall 368 76.0 116 24.0
technique with the remainder of the scale on the blade after
the KOH smear was prepared. The media were incubated at
25
◦C and room humidity. Cultures were read at weeks 1, 2,
and 3. For cultures with growth, a lactophenol-cotton blue
preparationwasmade.Fungiwereidentiﬁedonmacroscopic
(i.e., color, texture, rate of growth, pigment production)
and microscopic (i.e., microconidia, macroconidia, hyphal
elements) morphology.
2.3.Sensitivity,Speciﬁcity,PositivePredictiveValue(PPV),and
Negative Predictive Value (NPV). Using clinical assessment
as a gold standard, sensitivity and speciﬁcity were deter-
minedforKOHsmearandcultureforeachcomponentstudy
andfortheoverallcombineddata.Priortocalculatingoverall
sensitivity and speciﬁcity, a chi-square test for heterogeneity
was performed to determine if it was legitimate to pool data
from the individual studies [7]. Sensitivity was deﬁned as the
proportion of clinically negative assessments that screened
n e g a t i v ef o rK O Hs m e a ro rc u l t u r e .S p e c i ﬁ c i t yw a sd e ﬁ n e d
as the proportion of clinical failures that screened positive
for KOH smear or culture. Each sensitivity estimate was
accompanied by exact 95% binomial conﬁdence limits.4 Dermatology Research and Practice
Table 4: Cure rates at six weeks by study.
Study N KOH Negative Culture Negative Mycologic Cure
∗ Clinical Cure
N % N % N % N %
STUDY #1 99 81 82 27 27 24 24 45 45
STUDY #2 85 64 75 31 36 29 34 41 48
STUDY #3 81 50 62 19 23 19 23 18 22
STUDY #4 82 51 62 28 34 24 29 37 45
STUDY #5 113 48 43 34 30 26 23 46 41
Overall 460 294 64 139 30 122 27 187 41
∗Mycologic cure is deﬁned as negative KOH smear and negative culture.
Prior to calculating KOH smear and culture sensitivity,
speciﬁcity, PPV, and NPV, sensitivity and speciﬁcity generat-
ing cross-tabs from the component studies Tables 5(b)–5(f)
were subjected to chi-square tests for heterogeneity with k-
1 degrees of freedom (where k = number of component
studies). If the chi-square heterogeneity statistics (χ2
α,k−1)
were not statistically signiﬁcant (P>. 05), it would be
legitimate to pool the component study data. The χ2
0.05,4
value for culture sensitivity, speciﬁcity, PPV, NPV, and
spontaneous cure rate was 0.233 (P = .97) while that for
KOH smear parameters was 7.427 (P = .11). It was thus
permissible to calculate sensitivity and speciﬁcity for the
pooled study data.
2.4. Data Analysis. All statistical procedures were performed
as two-tailed tests using the SAS statistical package, Version
8.2. Diﬀerences were considered statistically signiﬁcant if
P<. 05.
3. Results
3.1.StudyPopulation. The484vehiclepatientsinthispooled
analysis represented 26% of the patient population of the
combined studies (N = 1,884). There were no major
diﬀerenceswithregardtodemographicvariablesbetweenthe
patients randomized to active treatment or vehicle in any of
the component studies. The age of the study patients ranged
from 18 to 83 years with a mean of 38.6 ± 13.1 (SD) years
(Table 1). The race proportions were 68% Caucasian, 10%
Black, 20% Hispanic, and 2% other (Table 2). Males (N =
368) comprised 76% of this population, while females (N =
116) comprised the other 24% (Table 3). The demographic
breakdowns within the component studies were for the most
part consistent.
3.2. Sensitivity and Speciﬁcity. Twenty-four patients were
eliminated from evaluation due to incomplete follow-up.
Among the 460 patients with complete data, 294 (64%) had
a negative KOH smear at 6 weeks, 139 (30%) had negative
culture results, and the number with clinically negative
exams was 187 (41%) (Table 4).
Using clinical assessment as the gold standard, the
sensitivities for KOH smear and culture were 73.3% (95%
CI: 66.3 to 79.5%) and 41.7% (34.6 to 49.1%), respectively
(Table 5). The diﬀerence between the KOH smear and
culture sensitivities was statistically signiﬁcant (P<. 0001,
2-tailed Fishers exact test). The culture sensitivities of the
component studies were conﬁned to a relatively narrow
range of 39.1 to 46.3% while those for the KOH smear varied
more widely from 58.7 to 91.3%. The highest individual
culture sensitivity, 46.3%, was lower than the lowest KOH
smear sensitivity of 58.7%. The respective speciﬁcities for
culture and KOH smear were 77.7% (72.2% to 82.5%) and
42.5% (36.6% to 48.6%). The diﬀerence between the culture
and KOH smear speciﬁcities was also statistically signiﬁcant
(P<. 0001). The culture speciﬁcities of the component
studies were again conﬁned to a narrow range of 71.1%
to 83.3% while those for the KOH smear varied more
widely from 20.5% to 68.7%. The highest individual KOH
smear speciﬁcity, 68.7%, was lower than the lowest culture
speciﬁcity of 71.1%.
3.3. Positive and Negative Predictive Value. Table 5 shows the
positive predictive value (PPV) and negative predictive value
(NPV)calculationsfortheoverallcombinedpopulationwith
complete data (N = 460). The PPV of culture was 66.0%
(95% CI: 60.6%–71.2%) and the NPV of culture was 56.1%
(95% CI: 47.4%–64.5%). The PPV of KOH smear was 69.9%
(95% CI: 62.3%–76.7%) and the NPV of KOH smear was
46.6% (95% CI: 40.8%–52.5%). The diﬀerence between the
KOH smear and culture NPV was not statistically signiﬁcant
(P = .08, 2-tailed Fishers exact test). The diﬀerence bet-
ween the KOH smear and culture PPV was not statistically
signiﬁcant (P = .42, 2-tailed Fishers exact test).
4. Discussion
There are 4 major subtypes of tinea pedis: interdigital,
moccasin, ulcerative, and inﬂammatory. Depending on the
particular subtype of disease with which a patient presents,
a clinician is faced with a subset of diﬀerential diagnoses
to consider, including allergic contact dermatitis, dyshidrotic
eczema,candidiasis,psoriasis,erythrasma,andkeratoderma.
Likely as a result of the broad scope of this diﬀerential,
several studies have found that clinical suspicion alone
is often insuﬃcient to diagnose tinea pedis [3]. Indeed,
conventional dermatology espouses that positive fungal
culture is necessary for deﬁnitive diagnosis [3–5].
Ourstudyexamines thesensitivity andspeciﬁcityofboth
KOH smear and fungal culture in determining the presenceDermatology Research and Practice 5
Table 5: Sensitivity, speciﬁcity, and predictive value for KOH smear and culture with clinical cure at six weeks as gold standard overall and
for component studies (a–f).
(a) Overall (N = 460).
Clinical Cure
Yes No Total
Culture
Neg 78 61 139
Pos 109 212 321
Total 187 273 460
SENSITIVITY (%) 41.7 (34.6–49.1)
∗∗
SPECIFICITY (%) 77.7 (72.2–82.5)
PV Neg (%)
∗ 56.1 (47.4–64.5)
PV Pos (%) 66.0 (60.6–71.2)
Neg 137 157 294
KOH Smear Pos 50 116 166
Total 187 273 460
SENSITIVITY (%) 73.3 (66.3–79.5)
SPECIFICITY (%) 42.5 (36.6–48.6)
PV Neg (%) 46.6 (40.8–52.5)
PV Pos (%) 69.9 (62.3–76.7)
∗PV = Predictive value, Neg = Negative, Pos = Positive
∗∗Point estimate with exact 95% binomial conﬁdence limits.
(b) Study STUDY #1 (N = 100).
Clinical Cure
Yes No Total
Culture
Neg 18 9 27
Pos 28 45 73
Total 46 54 100
SENSITIVITY (%) 39.1 (25.1–54.6)
SPECIFICITY (%) 83.3 (70.7–92.1)
PV Neg (%) 66.7 (46.0–83.5)
PV Pos (%) 61.6 (49.5–72.8)
KOH Smear
Neg 42 40 82
Pos 4 14 18
Total 46 54 100
SENSITIVITY (%) 91.3 (79.2–97.6)
SPECIFICITY (%) 25.9 (15.0–39.7)
PV Neg (%) 51.2 (39.9–62.4)
PV Pos (%) 77.8 (52.4–93.6)
(c) Study STUDY #2 (N = 81).
Clinical Cure
Yes No Total
Culture
Neg 19 12 31
Pos 22 32 54
Total 41 44 85
SENSITIVITY (%) 46.3 (30.7–62.6)
SPECIFICITY (%) 72.7 (57.2–85.0)
PV Neg (%) 61.3 (42.2–78.2)
PV Pos (%) 59.3 (45.0–72.4)6 Dermatology Research and Practice
(c) Continued.
Clinical Cure
Yes No Total
Neg 29 35 64
KOH Smear Pos 12 9 21
Total 41 44 85
SENSITIVITY (%) 70.7 (54.5–83.9)
SPECIFICITY (%) 20.5 (9.8–35.3)
PV Neg (%) 45.3 (32.8–58.3)
PV Pos (%) 42.9 (21.8–66.0)
(d) Study STUDY #3 (N = 81).
Clinical Cure
Yes No Total
Culture
Neg 8 11 19
Pos 10 52 62
Total 18 63 81
SENSITIVITY (%) 44.4 (21.5–69.2)
SPECIFICITY (%) 82.5 (70.9–90.9)
PV Neg (%) 42.1 (20.3–66.5)
PV Pos (%) 83.9 (72.3–92.0)
KOH Smear
Neg 15 35 50
Pos 3 28 31
Total 18 63 81
SENSITIVITY (%) 83.3 (58.6–96.4)
SPECIFICITY (%) 44.4 (31.9–57.5)
PV Neg (%) 30.0 (17.9–44.6)
PV Pos (%) 90.3 (74.2–98.0)
(e) Study STUDY #4 (N = 82).
Clinical Cure
Yes No Total
Culture
Neg 15 13 28
Pos 22 32 54
Total 37 45 82
SENSITIVITY (%) 40.5 (24.8–57.9)
SPECIFICITY (%) 71.1 (55.7–83.6)
PV Neg (%) 53.6 (33.9–72.5)
PV Pos (%) 59.3 (45.0–72.4)
KOH Smear
Neg 25 26 51
Pos 12 19 31
Total 37 45 82
SENSITIVITY (%) 67.6 (50.2–82.0)
SPECIFICITY (%) 42.2 (27.7–57.9)
PV Neg (%) 49.0 (34.8–63.4)
PV Pos (%) 61.3 (42.2–78.2)
(f) Study STUDY #5 (N = 113).
Clinical Cure
Yes No Total
Culture
Neg 18 16 34
Pos 28 51 79
Total 46 67 113Dermatology Research and Practice 7
(f) Continued.
Clinical Cure
Yes No Total
SENSITIVITY (%) 39.1 (25.1–54.6)
SPECIFICITY (%) 76.1 (64.1–85.7)
PV Neg (%) 52.9 (35.1–70.2)
PV Pos (%) 64.6 (53.0–75.0)
KOH Smear
Neg 27 21 48
Pos 19 46 65
Total 46 67 113
SENSITIVITY (%) 58.7 (43.2–73.0)
SPECIFICITY (%) 68.7 (56.2–79.4)
PV Neg (%) 56.3 (41.2–70.5)
PV Pos (%) 70.8 (58.2–81.4)
or absence of tinea pedis, using clinical assessment as the
gold standard. While useful as a gold standard to compare
sensitivity and speciﬁcity of KOH smear and culture, clinical
disease alone cannot be regarded as a perfect gold standard
because a wide variety of nondermatophyte conditions cause
identical clinical symptoms. In this study, entrance criteria
required positive culture, KOH, and clinical assessment.
Creams used were placebo. Therefore, any clinically positive
subject at week 4 or 6 would likely be positive because of
tinea rather than other conditions. Using KOH examination
or fungal culture as gold standards for diagnosis is also
problematic. It is possible for culture to be negative even in
the presence of active disease. This is supported by the fact
that 59 of the 460 patients enrolled in this study had negative
cultures at day 28 of the study, but positive cultures at day
42. It is likely that a large proportion of these patients had
false negative cultures at day 28. The data from our studies
also indicate that, in 185 out of 460 (40.2%) patients, KOH
smearandfungalcultureresultsdidnotcorrelateatday42of
the study. Finally, one could consider using clinical positive
AND KOH positive as the gold standard for culture, and
clinical positive AND culture positive as the gold standard
for KOH. In this way, the gold standard might reﬂect the
actual presence or absence of disease better than clinical
assessment alone.
The perfect gold standard for infection must be a triple
conﬁrmation: positive KOH smear, positive culture, and a
clinical exam consistent with tinea pedis. The results of our
pooled analysis show KOH smear and fungal culture to be
complementary laboratory exams, with higher sensitivity in
the former test, and higher speciﬁcity in the latter.
One strength of our study was that the pooled analysis
was done on data from 5 studies that shared amongst them
oneclinicalinvestigatorandonelaboratoryperformingKOH
smears and fungal cultures. The consistency of the results
a m o n g s te a c ho ft h e5s t u d i e s( Table 4) conﬁrms the validity
of our results. Having all 5 studies completed at the same
investigativecenterisalsoapotentialweaknessofthestudyas
it becomes harder to extrapolate the results to other clinical
settings.ThisisparticularlytruefortheNPVandPPV,which
are both related to disease prevalence in a particular popula-
tion. It is unclear if the NPV and PPV can be extrapolated to
other regions without knowing their local disease prevalence
rates. Additionally, sensitivity and speciﬁcity are only as
good as the person performing the exam. Our ﬁndings
were reached at the hands of skilled laboratory technicians.
Less experienced observers would be expected to have lower
sensitivity and speciﬁcity rates for their tests.
KOH smear serves as a good screening test for deter-
mining presence of disease, both before and at the end of
therapy. A fungal culture, which can take up to three weeks
to become positive, can serve as a more speciﬁc conﬁrmatory
test.Thecostsofempirictreatmentwithouteitherlaboratory
test include the risk of missing an alternate diagnosis and
the cost of medication used to treat a nonexistent tinea
infection. Still, many suspected cases of tinea pedis are
treated empirically, either by medications prescribed by
physicians or by patients self-treating with over-the-counter
medications. Given the imperfect sensitivity of KOH, this
strategyisnotcompletelyinvalid;however,thosewhoplacea
high value on KOH may still contend, and justiﬁably so that
an alternate diagnosis can be arrived at more quickly in the
presence of a negative KOH.
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